DiaGenic Drops as Alzheimer’s Test Study Misses Goal: Oslo Mover
This article is for subscribers only.
DiaGenic ASA, a Norwegian in-vitro diagnostics company, dropped the most on record in Oslo after saying that its MCItect test for early stage Alzheimer’s Disease unexpectedly failed to meet the objectives of a patient study.
“Final study results are still in progress, but it is clear that the current version of MCItect has not demonstrated the diagnostic accuracy we deem is required for CE-marking, U.S. studies and commercialization,” Chief Executive Officer Paul de Potocki said in a statement today. “A back-up program for a modified version of MCItect has been prepared and may be quickly initiated.”